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Objectives: This paper aims to describe the synthesis of a
series of novel 5-substituted dihydropyrimidine de-
rivatives using Fe-(III)-montmorillonite as an efficient
and reusable catalyst.
Methods: The structures of the synthesized compounds
were confirmed by Fourier transform-infrared spectros-
copy (FT-IR), nuclear magnetic resonance (NMR) and
mass spectroscopy methods. The title compounds were
screened for antimicrobial activity, and molecular dock-
ing studies were conducted.
Results: The results revealed that the catalyst signifi-
cantly enhanced the reaction time and product yield. The
antimicrobial activity results indicated that compounds
4c, 4e and 4k exhibited promising antimicrobial activity
against the tested microorganisms.
Conclusion: The catalyst can be recycled at least two to
three times without a noticeable decrease in its catalytic
activity. The synthesized compounds displayed promising
antimicrobial activity.
Keywords: 5-Substituted dihydropyrimidine; Antimicrobial
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Fe(III)-montmorillonite [Fe(III)-mont] is an environ-
mentally benign and heterogeneous catalyst used in the field
of synthetic organic chemistry. Fe(III)-mont clay is harmless
and chemically versatile and can be used as an efficient
catalyst in various reactions, such as FriedeleCrafts,1 Dielse
Alder2,3 and Michael addition,4 and these types of reactions
comply with green chemistry protocols.
Barbitone and thiobarbitone are biologically active com-
pounds that are capable of condensing with a wide range of
carbonyl compounds.5e7 The condensed barbiturates and
thiobarbiturates exhibit pharmacological profiles, such as
antimicrobial, antioxidant, antineoplastic, anticancer,
antitumour, antitubercular, antiinflammatory, antiviral, and
DNA cleavage activities, and are used in agrochemicals and
veterinary products.8e15 Earlier, our research group synthe-
sized different derivatives of benzofuran bearing the barbitone
and thiobarbitone moieties, screened them for antimicrobial
activity and completed a molecular docking study.16
Materials and Methods
Preparation of the Fe(III)-mont catalyst
Raw clay Na-mont was purchased fromKunipia F, Japan,
and its cation exchange capacity (CEC) was approximately
113 meq./100 g. The approximate chemical composition of the
clay mineral was given as (Na0.431K0.002Ca0.002) (Al1.56
Mg0.305Fe0.099Ti0.007)
oct (Si3.949Al0.051)
tet O10 (OH)2 nH2O.
Rawclay (20g)wasmixedwitha1MsolutionofFeCl3, and the
reactionmixture was continuously stirred for 24 h. The formed
claywas filtered, dried in a hot air oven at 40 Cand stored in a
desiccator until further use.17,18
Procedure for the synthesis of 5-substituted
dihydropyrimidine derivatives
Aldehyde (1 mmol) and barbituric/thiobarbituric acid
(1 mmol) in ethanol with the Fe(III)-mont (50% w/w) cata-
lyst were added to a solution of substituted acetophenones
(1 mmol), and the reaction mixture was stirred for 7 h at
80 C. After reaction completion (monitored by TLC), the
reaction mixture was cooled and poured into crushed ice.
The product was extracted with ethyl acetate, dried and
recrystallized using ethanol.
5-[1-Phenyl-3-(thiophen-2-yl)prop-2-en-1-ylidene]-2-
thioxodihydropyrimidine-4,6(1H,5H)-dione (4a)
Light yellow solid; mp 210e212 C; IR (cm1): 3317
(NeH), 1655 (C]O), 1672 (eNHC]O), 1351(C]S); 1H
NMR (400 MHz) d ppm: 5.67 (d, 2H), 7.65 (m, 3H), 7.92 (d,
J ¼ 8.62 Hz, 2H), 7.98 (t, J ¼ 8.76 Hz, 1H), 8.02 (d,
J ¼ 8.36 Hz, 2H), 9.15 (s, 2H barbituric-NH); 13C NMR
(300 MHz) d ppm: 32.3, 126.4, 131.2, 133.5, 146.8, 150.8,
163.6, 166.6, 178.1; LCMS: m/z 340.22 [Mþ].
5-[1-(4-Methylphenyl)-3-(thiophen-2-yl)prop-2-en-1-ylidene]-2-
thioxodihydropyrimidine-4,6(1H,5H)-dione (4b)
White solid; mp 225e226 C; IR (cm1): 3320, 1680, 1685,
1342; 1H NMR, d ppm: 3.54 (s, 3H, CH3), 7.38 (t, 1H), 7.55(m, Hz, 3H), 7.74 (t, J ¼ 8.44 Hz, 2H), 7.88 (m, J ¼ 8.48 Hz,
2H), 8.33 (s, 1H), 9.59 (s, 2H); 13C NMR, d ppm: 112.7,
116.4, 121.4, 127.2, 130.1, 135.8, 145.8, 155.5, 183.7; LCMS:
m/z 354.12 [Mþ].
5-[1-(4-Chlorophenyl)-3-(thiophen-2-yl)prop-2-en-1-ylidene]-2-
thioxodihydropyrimidine-4,6(1H,5H)-dione (4c)
Yellow solid; mp 261e262 C; IR (cm1): 3317, 1672,
1682, 1325; 1H NMR, d ppm: 5.62 (d, 2H), 7.18 (m, 3H), 7.68
(t, J ¼ 8.44 Hz, 1H), 7.95 (t, J ¼ 9.40 Hz, 1H), 8.03 (d,
J ¼ 8.56 Hz, 2H) 9.15 (s, 2H); 13C NMR, d ppm: 32.4, 120.8,
136.1, 140.2, 145.0, 148.4, 155.2, 160.1, 164.3, 176.4; LCMS:
m/z 376.42 [Mþ2].
5-[1-(4-Fluorophenyl)-3-(thiophen-2-yl)prop-2-en-1-ylidene]-2-
thioxodihydropyrimidine-4,6(1H,5H)-dione (4d)
White solid; mp 232e233 C; IR (cm1): 3322, 1669, 1680,
1323; 1H NMR, d ppm: 5.58 (d, 2H), 7.19 (m, 3H), 7.65 (t,
J ¼ 8.64 Hz, 2H), 7.84 (d, J ¼ 9.40 Hz, 2H), 9.04 (s, 2H); 13C
NMR, d ppm: 34.5, 122.3, 130.6, 141.9, 142.5, 146.2, 149.5,
157.3, 163.2, 177.3; LCMS: m/z 358.22 [Mþ].
5-[1-(4-Nitrophenyl)-3-(thiophen-2-yl)prop-2-en-1-ylidene]-2-
thioxodihydropyrimidine-4,6(1H,5H)-dione (4e)
White solid; mp 272e273 C; IR (cm1): 3342, 1678, 1669,
1322; 1H NMR, d ppm: 5.46 (d, 2H), 7.15 (m, 3H), 7.14 (d,
J ¼ 8.96 Hz, 2H), 7.42 (t, J ¼ 8.12 Hz, 2H), 9.09 (s, 2H); 13C
NMR, d ppm: 33.6, 124.1, 129.7, 142.9, 145.8, 148.2, 153.2,
156.1, 163.8, 175.2; LCMS: m/z 385.62 [Mþ].
5-[1-(4-Methoxyphenyl)-3-(thiophen-2-yl)prop-2-en-1-ylidene]-2-
thioxodihydropyrimidine-4,6(1H,5H)-dione (4f)
Brown solid; mp 286e287 C; IR (cm1): 3339, 1666,
1682, 1320; 1H NMR d ppm: 3.76 (s, 3H), 5.86 (d, 2H), 7.12
(m, 3H), 7.15 (d, J ¼ 8.24 Hz, 2H), 7.39 (t, J ¼ 8.12 Hz, 2H),
9.12 (s, 2H); 13C NMR, d ppm: 30.1, 126.3, 128.9, 141.2,
144.2, 147.1, 157.5, 161.2, 164.3, 176.1; LCMS: m/z 370.58
[Mþ].
5-[3-(Furan-2-yl)-1-phenylprop-2-en-1-ylidene]-2-
thioxodihydropyrimidine-4,6(1H,5H)-dione (4g)
Light yellow solid; mp 216e217 C; IR (cm1): 3318,
1658, 1671, 1353; 1H NMR, d ppm: 5.86 (d, 2H), 7.42 (m,
3H), 7.82 (d, J¼ 8.42 Hz, 2H), 7.92 (t, J¼ 8.22 Hz, 1H), 8.10
(d, J ¼ 8.28 Hz, 2H), 9.12 (s, 2H); 13C NMR, d ppm: 31.5,
124.2, 132.3, 135.1, 137.1, 145.3, 149.2, 162.5, 165.9, 179.2;
LCMS: m/z 324.16 [Mþ].
5-[3-(Furan-2-yl)-1-(4-methylphenyl)prop-2-en-1-ylidene]-2-
thioxodihydropyrimidine-4,6(1H,5H)-dione (4h)
White solid; mp 245e246 C; IR (cm1): 3323, 1685, 1689,
1345; 1H NMR, d ppm: 2.48 (s, 3H, CH3), 5.66 (d, 2H), 7.68
(m, 3H), 7.86 (d, J ¼ 8.64 Hz, 2H), 8.12 (d, J ¼ 8.42 Hz, 2H),
9.03 (s, 2H); 13CNMR, d ppm: 31.2, 126.5, 137.1, 140.2, 145.8,
152.4, 156.1, 163.4, 166.4, 172.8; LCMS: m/z 338.89 [Mþ].
5-[1-(4-Chlorophenyl)-3-(furan-2-yl)prop-2-en-1-ylidene]-2-
thioxodihydropyrimidine-4,6(1H,5H)-dione (4i)
Yellow solid; mp 258e259 C; IR (cm1): 3321, 1673,
1681, 1329; 1H NMR, d ppm: 5.59 (d, 2H), 7.71 (m,
J ¼ 8.56 Hz, 3H), 7.96 (d, J ¼ 9.12 Hz, 2H), 8.03 (d,
J ¼ 8.56 Hz, 2H) 9.08 (s, 2H); 13C NMR, d ppm: 31.2, 125.6,
Fe(III)-montmorillonite catalysed one pot synthesis62137.2, 141.3, 148.2, 156.7, 158.1, 162.9, 165.2, 176.1; LCMS:
m/z 360.14 [Mþ2].
5-[1-(4-Fluorophenyl)-3-(furan-2-yl)prop-2-en-1-ylidene]-2-
thioxodihydropyrimidine-4,6(1H,5H)-dione (4j)
White solid; mp 228e229 C; IR (cm1): 3341, 1672, 1688,
1332; 1H NMR, d ppm: 5.69 (d, 2H), 7.26 (m, J ¼ 8.12 Hz,
3H), 7.60 (t, J¼ 8.34 Hz, 2H), 7.89 (d, J¼ 9.62 Hz, 2H), 9.05
(s, 2H); 13C NMR, d ppm: 32.1, 123.5, 131.4, 142.8, 145.9,
148.2, 157.2, 163.5, 164.1, 178.2; LCMS: m/z 342.52 [Mþ].
5-[3-(Furan-2-yl)-1-(4-nitrophenyl)prop-2-en-1-ylidene]-2-
thioxodihydropyrimidine-4,6(1H,5H)-dione (4k)
Brown solid; mp 281e282 C; IR (cm1): 3339, 1665,
1670, 1323; 1H NMR, d ppm: 5.55 (d, 2H), 7.18 (m, 3H), 7.46
(t, J ¼ 8.18 Hz, 2H), 7.55 (d, J ¼ 8.74 Hz, 2H), 9.11 (s, 2H);
13C NMR, d ppm: 32.1, 126.5, 129.2, 141.2, 143.5, 148.5,
153.5, 158.6, 164.2, 174.1; LCMS: m/z 369.82 [Mþ].
5-[3-(Furan-2-yl)-1-(4-methoxyphenyl)prop-2-en-1-ylidene]-2-
thioxodihydropyrimidine-4,6(1H,5H)-dione (4l)
White solid; mp 264e266 C; IR (cm1): 3346, 1672, 1689,
1326; 1H NMR, d ppm: 5.52 (d, 2H), 7.11 (m, 3H), 7.26 (d,
J ¼ 8.16 Hz, 2H),7.62 (t, J ¼ 8.34 Hz, 2H), 9.12 (s, 2H); 13C
NMR, d ppm: 34.2, 125.8, 128.6, 143.8, 146.7, 149.1, 154.6,
158.2, 164.2, 176.1; LCMS: m/z 354.25 [Mþ].
5-[1-Phenyl-3-(thiophen-2-yl)prop-2-en-1-ylidene]pyrimidine-
2,4,6(1H,3H,5H)-trione (4m)
Yellow solid; mp 221e222 C; IR (cm1): 3319, 1656, 1674,
1352; 1H NMR, d ppm: 5.62 (d, 2H), 7.42 (m, 3H), 7.82 (d,
J¼ 8.16Hz, 2H), 7.96 (t, J¼ 8.86Hz, 1H), 8.12 (d, J¼ 8.24Hz,
2H), 9.12 (s, 2H); 13C NMR, d ppm: 33.6, 124.3, 133.6, 134.5,
147.4, 154.6, 164.7, 167.8, 179.6; LCMS: m/z 324.63 [Mþ].
5-[1-(4-Methylphenyl)-3-(thiophen-2-yl)prop-2-en-1-ylidene]
pyrimidine-2,4,6(1H,3H,5H)-trione (4n)
White solid; mp 216e217 C; IR (cm1): 3335, 1678, 1684,
1340; 1HNMR,dppm: 2.48 (s, 3H,CH3), 5.46 (d, 2H), 7.60 (m,
Hz, 3H), 7.84 (d, J ¼ 8.56 Hz, 2H), 8.05 (d, J ¼ 8.84 Hz, 2H),
9.10 (s, 2H); 13CNMR, d ppm: 31.5, 126.2, 134.2, 139.6, 143.2,
147.3, 155.1, 163.8, 166.4, 178.6; LCMS: m/z 338.25 [Mþ].
5-[1-(4-Chlorophenyl)-3-(thiophen-2-yl)prop-2-en-1-ylidene]
pyrimidine-2,4,6(1H,3H,5H)-trione (4o)
Yellow solid; mp 278e279 C; IR (cm1): 3319, 1676,
1686, 1322; 1H NMR, d ppm: 5.48 (d, 2H), 7.55 (m, 3H), 7.95
(d, J ¼ 9.56 Hz, 2H), 8.02 (t, J ¼ 9.40 Hz, 2H), 9.15 (s, 2H);
13C NMR, d ppm: 30.1, 121.5, 136.5, 141.3, 146.2, 149.2,
158.2, 161.2, 166.4, 177.6; LCMS: m/z 360.72 [Mþ2].
5-[1-(4-Fluorophenyl)-3-(thiophen-2-yl)prop-2-en-1-ylidene]
pyrimidine-2,4,6(1H,3H,5H)-trione (4p)
Brown solid; mp 236e237 C; IR (cm1): 3326, 1670,
1685, 1326; 1H NMR, d ppm: 5.53 (d, 2H), 7.12 (m, 3H), 7.29
(t, J ¼ 8.56 Hz, 2H), 7.68 (d, J ¼ 9.12 Hz, 2H), 9.11 (s, 2H);
13C NMR, d ppm: 32.6, 125.6, 130.2, 142.9, 143.6, 148.9,
156.8, 162.5, 164.6, 176.2; LCMS: m/z 342.76 [Mþ].
5-[1-(4-Nitrophenyl)-3-(thiophen-2-yl)prop-2-en-1-ylidene]
pyrimidine-2,4,6(1H,3H,5H)-trione (4q)
White solid; mp 289e290 C; IR (cm1): 3340, 1676, 1670,
1320; 1H NMR, d ppm: 5.58 (d, 2H), 7.19 (m, 3H), 7.44 (t,J ¼ 8.44 Hz, 2H), 7.64 (d, J ¼ 8.22 Hz, 2H), 9.05 (s, 2H); 13C
NMR, d ppm: 32.6, 124.6, 125.1, 141.6, 149.5, 154.3, 157.2,
163.5, 166.7, 176.1; LCMS: m/z 369.35 [Mþ].
5-[1-(4-Methoxyphenyl)-3-(thiophen-2-yl)prop-2-en-1-ylidene]
pyrimidine-2,4,6(1H,3H,5H)-trione (4r)
White solid; mp 292e293 C; IR (cm1): 3332, 1675, 1668,
1324; 1H NMR, d ppm: 5.16 (d, 2H), 7.19 (m, 3H), 7.16 (d,
J ¼ 8.76 Hz, 2H), 7.45 (t, J ¼ 8.16 Hz, 2H), 9.12 (s, 2H); 13C
NMR, d ppm: 33.9, 124.6, 125.6, 141.6, 144.8, 146.4, 154.1,
163.5, 164.6, 178.1; LCMS: m/z 354.82 [Mþ].
Antibacterial and antifungal activity
The synthesized compounds were screened for their
antimicrobial activity using the agar well diffusion method.19
The antibacterial activity test was performed against the
Gram-positive bacteria Streptococcus pneumoniae and Ba-
cillus subtilis and the Gram-negative bacteria Escherichia coli
and Pseudomonas aeruginosa. The antifungal activity was
screened against three fungal strains, Phytophthora meadii,
Candida albicans and Trichophyton rubrum. All of the bac-
terial and fungal strains were procured from NCL in Pune,
India. The bacterial cultures were inoculated on nutrient
agar, and the fungal cultures were inoculated on potato
dextrose agar media. The test compounds were dissolved in
DMSO at a concentration of 1000 mg/mL, and 100 mL of this
sample were loaded directly into the wells of the agar plates.
The plates inoculated with the bacterial strains were incu-
bated at 37 C for 24 h, and the fungal strain cultures were
incubated at 25 C for 72 h. Ciprofloxacin and fluconazole
were used as the standard drugs for the antibacterial and
antifungal activities, respectively. All determinations were
performed in triplicate.
In silico molecular docking studies
The protein databank (PDB) coordinate file entitled
‘2XCT.pdb’ was used as the receptor (protein) molecule. The
file is a structure of Staphylococcus aureus gyrase in complex
with ciprofloxacin and DNA.20 The AutoGrid 4.0 Program,
supplied with AutoDock 4.0, was used to produce the grid
maps.21 All of the AutoDock docking runs were performed
on a Core i7 Intel processor CPU with 16 GB DDR3l
RAM. The AutoDock Vina was compiled and run on the
Windows 8.0 professional operating system. LigPlotþ22
and PyMol23 were used to render the pictorial repre-
sentations of the interactions between the ligands and the
target protein.
Results
We have developed a novel route for the synthesis of 5-
substituted dihydropyrimidine derivatives using Fe(III)-
mont as an efficient catalyst. The reaction of acetophe-
nones, aldehydes and barbituric/thiobarbituric acid was first
selected as the model transformation (Scheme 1) to optimize
the reaction conditions.
Initially, we synthesized compound 4a in the absence of a
catalyst, but we only obtained low yields after a prolonged
reaction time (Table 1). Next, the reactions were carried out
Table 1: Optimization of the reaction conditions for compound
4a.
Entry Fe(III)-mont
(w/w%)
Temperature
(C)
Time
(h)
Yield
(%)
1 0 80 16 22
2 5 80 13 40
3 10 80 10 49
4 25 80 8 71
5 50 80 7 86
6 75 80 8 65
V. B.M. et al. 63in the presence of the catalyst at different concentrations.
With 5 w/w% of the catalyst, we obtained a considerable
yield (40%) with a reduced reaction time of 13 h. Further
increases in the catalyst amount from 5 to 10 and 25 w/w
% further increased the yield (49 and 71%) and decreased
the reaction time. When the amount of catalyst was
increased to 50 w/w%, the product yield dramatically
increased to 86%. However, when the catalytic amount
increased to 75 w/w%, a reduction in the product yield
(65%) and an increase in the reaction time were observed.
Based on these results, we concluded that 50 w/w% of the
catalyst gave the best product yield with the shortest
reaction time. Using these optimized conditions, several 5-
substituted dihydropyrimidine derivatives were synthesized,
and the results are summarized in Table 2.
We also investigated the regeneration of the catalyst at the
end of the reaction (Table 3). After reaction completion, the
final compound was extracted with ethyl acetate, and the
catalyst was retrieved. The catalyst regenerated from the
reaction mixture was washed with H2O, dried and reused
for a new reaction cycle. The efficiency of the catalyst with
respect to the yield of compound 4b was 86, 62 and 44%
for the first, second and third uses, respectively.In vitro antimicrobial study
The newly synthesized compounds were screened for their
antimicrobial activity. The results are tabulated in Table 4,
and the MIC values of the synthesized compounds are
shown in Table 5. The antibacterial results revealed that
compound 4c was the most effective against all of the
bacterial strains, with MIC values ranging from 12.42 to
21.32 mg/mL. Compounds 4e and 4k showed promising
activity against the bacteria P. aeruginosa, with MIC values
of 14.22 and 16.36 mg/mL, respectively. Compounds 4i and
4o displayed moderate to good antibacterial activity
against all of the pathogenic microorganisms, with MIC
values ranging from 18.42 to 26.53 mg/mL. The antifungal
activity results revealed that compound 4c was the most
effective against the fungal strains P. meadii and T. rubrum,
with MIC values of 29.15 and 26.42 mg/mL, respectively.
Compounds 4e, 4k and 4o displayed good activity againstR
O
+
X
O
+ NH
NH
OO
X1
1 2 3
R X X   R X 
4a -H S S 4j -F O 
4b -CH  S S 4k -NO  O 
4c -Cl S S 4l -OCH  O 
4d -F S S 4m -H S 
4e -NO  S S 4n -CH  S 
4f -OCH  S S 4o -Cl S 
4g -H O S 4p -F S 
4h -CH  O S 4q -NO  S 
4i -Cl O S 4r -OCH  S 
Scheme 1: Synthetic routethe tested fungal strains, with MIC values ranging from
29.97 to 46.43 mg/mL.In silico molecular docking study
The molecular docking study results are tabulated in
Table 6. The results show that compound 4k establishes three
hydrogen bonds with Ser1085, Gly1082 and His1081 in the
active site of the target protein with minimum bond lengths
(3.09, 3.16 and 3 A˚, respectively), and compound 4k has
the highest affinity and, thus, the best dock conformation.
Compound 4e establishes two hydrogen bonds with Ser438
and Asp437 with bond lengths of 2.98 and 3.06 A˚.
Compound 4c establishes one hydrogen bond with Asp437
with a bond length of 3.30 A˚. Among the docked
molecules, compounds 4c and 4k showed more
hydrophobic interactions with the tested protein, while the
other compounds showed minimal hydrophobic
interactions. All of the docked molecules have zero root
mean square deviation values, which indicate the true
binding poses of the molecules with the protein. Figure 1
and Figure 2 represent the 2D and 3D interactions of
compounds 4k, 4e, 4c and ciprofloxacin with gyrase (2XCT).Discussion
A series of 5-substituted dihydropyrimidine derivatives
was synthesized using the Fe(III)-mont catalyst. The catalyst
significantly improved the synthetic methodology in terms ofFe(III)-mont
EtOH, 80 
o
C
R
X
NH NH
O O
X1
4a-r
X
S  
S  
S  
O  
O  
O  
O  
O  
O
for target molecules.
Table 2: One pot synthesis of 5-substituted dihydropyrimidine derivatives catalysed by Fe(III)-mont.a
Entry Acetophenone Aldehyde Compounds Product Timeb (wh) Yield (%)
1
H
O
Thiophene-2-carbaldehyde 4a
NH NH
S
OO
H
S
7 78
2
O
Thiophene-2-carbaldehyde 4b
NH NH
S
OO
S
7 86
3
Cl
O
Thiophene-2-carbaldehyde 4c
NH NH
S
OO
Cl
S
7 80
4
F
O
Thiophene-2-carbaldehyde 4d
NH NH
S
OO
F
S
7 76
5
O N
O
Thiophene-2-carbaldehyde 4e
NH NH
S
OO
O2N
S
7 83
6
H CO
O
Thiophene-2-carbaldehyde 4f
NH NH
S
OO
H3CO
S
7 76
7
H
O
Furan-2-carbaldehyde 4g
NH NH
S
OO
H
O
7 86
8
O
Furan-2-carbaldehyde 4h
NH NH
S
OO
O
7 76
9
Cl
O
Furan-2-carbaldehyde 4i
NH NH
S
OO
Cl
O
7 82
10
F
O
Furan-2-carbaldehyde 4j
NH NH
S
OO
F
O
7 79
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Table 2 (continued )
Entry Acetophenone Aldehyde Compounds Product Timeb (wh) Yield (%)
11
O N
O
Furan-2-carbaldehyde 4k
NH NH
S
OO
O2N
O
7 84
12
H CO
O
Furan-2-carbaldehyde 4l
NH NH
S
OO
H3CO
O
7 85
13
H
O
Thiophene-2-carbaldehyde 4m
NH NH
O
OO
H
S
7 75
14
O
Thiophene-2-carbaldehyde 4n
NH NH
O
OO
S
7 84
15
Cl
O
Thiophene-2-carbaldehyde 4o
NH NH
O
OO
Cl
S
7 78
16
F
O
Thiophene-2-carbaldehyde 4p
NH NH
O
OO
F
S
7 77
17
O2N
O
Thiophene-2-carbaldehyde 4q
NH NH
O
OO
O N
S
7 80
18
H3CO
O
Thiophene-2-carbaldehyde 4r
NH NH
O
OO
H3CO
S
7 83
a Reaction conditions: acetophenone (1 mmol), aldehyde (1 mmol), 2-sulfanyl-1,3-benzoxazole-5-sulfonamide (1 mmol); solvent: ethanol;
catalyst: Fe(III)-mont (80 C).
b Time  20 min.
V. B.M. et al. 65the yield and reaction time. The screening of the antibacterial
and antifungal activities of the synthesized compounds 4aer
was accomplished using the agar well diffusion method. We
observed that most of the compounds exhibited good anti-
microbial activity and antifungal activity in the range of
12.13e99.73 mg/mL. Compound 4c exhibited the maximum
activity among all of the compounds with MIC values of12.42e29.15 mg/mL for antibacterial and antifungal activ-
ities. In compound 4c, the C]S group in the barbituric acid
and Cl in the para position significantly improved its anti-
microbial activity.
To correlate with the in vitro antimicrobial activity, in
silico studies were conducted to predict the binding affinity
and orientation at the active site of the receptor. The
Table 5: Minimum inhibition concentration (MIC) values for compo
Minimum inhibition concentration (mg/mL)
Compound E. c. P. a. S. p.
4a 92.22 55.53 41.42
4b 54.35 42.37 42.58
4c 21.32 16.64 12.42
4d 41.42 82.46 12.13
4e 21.43 14.22 18.54
4f 42.31 34.58 42.76
4g 95.54 74.23 64.31
4h 35.27 32.45 43.65
4i 26.53 24.16 18.42
4j 41.13 28.34 24.59
4k 19.52 16.36 21.46
4l 36.34 35.82 46.79
4m 89.53 78.92 82.73
4n 63.46 73.65 71.48
4o 26.23 25.43 20.76
4p 82.63 69.43 52.13
4q 62.36 45.22 38.51
4r 32.35 44.26 51.56
Stnda 6.53 5.23 6.21
Stndb e e e
Table 4: Antimicrobial activity data for the synthesized compounds.
Zone of inhibition
Compound E. c. P. a. S. p.
4a 10  0.1 14  0.2 20  0.2
4b 12  0.2 14  0.2 13  0.2
4c 20  0.1 21  0.1 22  0.2
4d 15  0.1 19  0.1 17  0.1
4e 22  0.2 20  0.2 21  0.2
4f 17  0.2 18  0.2 17  0.2
4g 13  0.1 10  0.2 12  0.2
4h 14  0.2 14  0.2 15  0.2
4i 15  0.1 16  0.2 16  0.1
4j 14  0.2 15  0.1 17  0.1
4k 20  0.1 21  0.2 24  0.2
4l 14  0.1 16  0.2 18  0.2
4m 14  0.2 15  0.2 19  0.2
4n 13  0.1 16  0.1 12  0.1
4o 19  0.1 20  0.1 20  0.2
4p 14  0.1 18  0.2 17  0.1
4q 20  0.2 19  0.2 20  0.2
4r 18  0.2 16  0.2 16  0.1
Stnda 26  0.2 28  0.1 27  0.1
Stndb e e e
Stnda: Ciprofloxacin, Stndb: Fluconazole.
E. c.: Escherichia coli, P. a.: Pseudomonas aeruginosa, S. p.: Streptococc
C. a.: Candida albicans, T. r.: Trichophyton rubrum.
Table 3: Efficiency of the catalyst.
Entry Product Fe(III)-mont
(w/w%)
Time (h) Yield (%)
1st/2nd/3rd
1 4b 50 7 86/62/44
Fe(III)-montmorillonite catalysed one pot synthesis66molecular docking of ligand molecules 4c, 4e and 4k with
gyrase revealed that all of the tested ligand molecules showed
encouraging binding energies and that the compounds
bonded with one or more amino acids in the active pockets,
as shown in Figures 1 and 2. Among the docked molecules,
compounds 4k and 4e were found to have the best docked
confirmations with the lowest binding affinity (5.5
and 5.8 kJ/mol).unds 4aer.
B. s. P. m. C. a. T. r.
47.93 81.56 63.26 72.53
28.64 72.85 65.74 24.92
22.45 29.15 31.65 26.42
73.87 92.54 43.28 41.64
21.46 40.62 31.12 31.67
39.56 54.43 69.83 52.73
88.65 72.28 94.17 99.73
34.78 84.62 64.26 59.15
20.64 49.72 52.46 43.27
34.58 76.24 32.34 36.77
23.46 41.26 34.64 29.97
40.53 43.46 53.46 42.78
87.34 81.76 79.67 28.96
49.73 82.87 84.64 73.62
21.43 39.25 32.65 46.43
63.84 92.55 63.22 54.65
48.45 60.22 65.18 52.69
49.52 61.47 59.86 72.75
5.36 e e e
e 11.25 9.36 12.35
B. s. P. m. C. a. T. r.
11  0.1 9  0.2 12  0.1 11  0.2
15  0.1 10  0.1 11  0.2 8  0.2
22  0.1 9  0.1 10  0.1 11  0.1
13  0.2 11  0.1 11  0.2 12  0.2
20  0.1 15  0.1 14  0.2 15  0.1
19  0.2 13  0.2 12  0.2 14  0.2
12  0.1 9  0.1 11  0.1 11  0.1
16  0.1 11  0.2 7  0.2 11  0.2
20  0.1 10  0.1 11  0.1 12  0.1
18  0.1 9  0.1 12  0.1 8  0.1
21  0.2 21  0.2 22  0.2 20  0.2
17  0.2 10  0.1 12  0.1 13  0.1
14  0.1 8  0.1 11  0.1 10  0.2
15  0.1 9  0.2 10  0.2 7  0.2
20  0.1 8  0.1 9  0.1 10  0.1
15  0.2 10  0.1 12  0.2 11  0.2
20  0.1 14  0.1 13  0.2 14  0.1
18  0.2 12  0.2 11  0.2 13  0.2
27  0.2 e e e
e 23  0.1 24  0.1 23  0.2
us pneumoniae, B. s.: Bacillus subtilis, aP. m.: Phytophthora meadii,
Figure 1: 2D representation of the interaction of compounds 4k, 4e, 4c and ciprofloxacin with gyrase (2XCT).
Table 6: In silico docking study of the synthesized compounds.
Ligand Affinity
(kcal/mol)
H-bonds H-bond
length (A˚)
H-bond between Hydrophobic interactions
4k 5.5 3 3.09 3c:OAZ::Ser1085:OG Asp437, Arg1122, Phe1123, Gly459, Asp512,
Glu435, Asp5103.16 3c:OAZ::Gly1082:N
3 3c:OAY::His1081:ND1
4e 5.8 2 2.98 3d:OAY::Ser438:N Lys460, Phe1123, Ile561, Gly459, Pro1080,
Glu435, Asp510, His1081, Gly4363.06 3d:OAY::Asp437:N
4c 5.7 1 3.30 3j:OAV::Asp437:N Gly436, Phe1123, Ile516, Glu435, Asp512
Ciprofloxacin 5.4 1 2.80 Cipro:OAT::His1081:ND1 Glu435, Asp437, Gly459, Lys460, Ile516,
Arg1122, Phe1123
V. B.M. et al. 67
Figure 2: 3D representation of the interaction of compounds 4k, 4e, 4c and ciprofloxacin with gyrase (2XCT).
Fe(III)-montmorillonite catalysed one pot synthesis68Conclusion
In our study, we described a one pot synthesis of 5-
substituted dihydropyrimidine derivatives via the reaction
of substituted acetophenones, aldehyde and barbituric/thio-
barbituric acid using ethanol as a solvent in the presence of
Fe(III)-mont as a catalyst. After standardization of the
procedure, we regenerated and reused the catalyst three
times. The antimicrobial studies revealed that the com-
pounds showed significant activity, and these results were
supported by the in silico molecular docking study.
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